S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

ASX:OSL - Oncosil Medical Stock Price, Forecast & News

A$0.16
+0.01 (+6.80 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
A$0.15
Now: A$0.16
A$0.16
50-Day Range
A$0.15
MA: A$0.17
A$0.21
52-Week Range
A$0.02
Now: A$0.16
A$0.22
Volume1.11 million shs
Average VolumeN/A
Market Capitalization$99.02 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for cancer in Australia. Its lead product is OncoSil, a brachytherapy device comprising OncoSil Phosphorous-32 Microparticles and OncoSil Diluent, which implants a pre-determined dose of beta radiation emitting isotope directly into cancerous tissue for the treatment of pancreatic and liver cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9223 3344

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.63 million
Cash FlowA$0.01 per share
Book ValueA$0.02 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$99.02 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OSL News and Ratings via Email

Sign-up to receive the latest news and ratings for OSL and its competitors with MarketBeat's FREE daily newsletter.


Oncosil Medical (ASX:OSL) Frequently Asked Questions

What is Oncosil Medical's stock symbol?

Oncosil Medical trades on the ASX under the ticker symbol "OSL."

Has Oncosil Medical been receiving favorable news coverage?

Media coverage about OSL stock has trended positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oncosil Medical earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Oncosil Medical.

Who are some of Oncosil Medical's key competitors?

What other stocks do shareholders of Oncosil Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncosil Medical investors own include Twitter (TWTR), Procter & Gamble (PG), WiseTech Global (WTC), Qube (QUB), Charter Hall Education Trust (CQE) and APA Group (APA).

Who are Oncosil Medical's key executives?

Oncosil Medical's management team includes the folowing people:
  • Mr. Daniel Kenny B.Sc., CEO, MD & Exec. Director
  • Mr. Tom Milicevic B.Comm, FCPA, MBA MGSM, CFO & Company Sec. (Age 47)
  • Mr. Michael Warrener, Global Sales & Marketing Director
  • Dr. Ashish Soman, Chief Medical Officer
  • Dr. David C. James, Global Head of Manufacturing Operations

What is Oncosil Medical's stock price today?

One share of OSL stock can currently be purchased for approximately A$0.16.

How big of a company is Oncosil Medical?

Oncosil Medical has a market capitalization of $99.02 million and generates $3.63 million in revenue each year. View Additional Information About Oncosil Medical.

What is Oncosil Medical's official website?

The official website for Oncosil Medical is http://www.oncosil.com.au/.

How can I contact Oncosil Medical?

The company can be reached via phone at 61 2 9223 3344.


MarketBeat Community Rating for Oncosil Medical (ASX OSL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  12 (Vote Underperform)
Total Votes:  25
MarketBeat's community ratings are surveys of what our community members think about Oncosil Medical and other stocks. Vote "Outperform" if you believe OSL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel